SCHEMBL6844898

SCHEMBL6844898

Cc1cc2c(cc1C(=O)O)CCN2c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.45
KCNQ2 O43526 1/20 0.40
LMNA P02545 5/20 0.39
MAPT P10636 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TP53 P04637 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 2/20 0.39
SRD5A1 P18405 1/20 0.39
SRD5A2 P31213 1/20 0.39
MEN1 O00255 1/20 0.39
PPARA Q07869 2/20 0.37
HTR7 P34969 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
KDM4E B2RXH2 1/20 0.37
SSTR5 P35346 1/20 0.36
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL698804 0.80 OPRM1 (0.47) NOTUMTP53SMN1; SMN2KMT2ASRD5A1
SCHEMBL27989184 0.76 LMNA (0.57) NOTUMLMNAMAPTTDP1TP53
SCHEMBL2610328 0.76 NOTUM (0.50) NOTUMLMNAMAPTTDP1TP53
SCHEMBL6844837 0.74 KDM4E (0.42) NOTUMLMNATP53SMN1; SMN2NPC1
SCHEMBL18002657 0.73 MEN1 (0.48) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL699408 0.73 SRD5A1 (0.57) NOTUMMAPTTP53SMN1; SMN2NPC1
SCHEMBL2610329 0.71 GPR52 (0.42) NOTUMLMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL5737436 0.70 ESR1 (0.45) NOTUMKCNQ2
SCHEMBL13063183 0.69 P2RX7 (0.39) NOTUMLMNAMAPTTDP1SMN1; SMN2
SCHEMBL18003058 0.68 ALDH1A1 (0.42) MAPTSMN1; SMN2RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362000-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-01-29 US disclosed
US-8362001-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-01-29 US disclosed
US-20110015171-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-01-20 US disclosed
US-20100331300-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015171-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA NOTUM 173/4885KCNQ2 1163/4885LMNA 2009/4885
US-20100331300-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA NOTUM 173/4885KCNQ2 1163/4885LMNA 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.